Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PharmaCyte Biotech, Inc. (PMCB)

PharmaCyte Biotech dismisses CBIZ CPAs, engages Grassi & Co. as new auditor

Neutral Impact 3 of 5 leadership Written later

PharmaCyte Biotech's Audit Committee dismissed CBIZ CPAs as its independent registered public accounting firm on October 14, 2026, and engaged Grassi & Co., CPAs as its replacement. The filing reports no adverse or qualified audit opinions from CBIZ CPAs for fiscal 2026 and 2025, but it discloses material weaknesses in internal control tied to segregation of duties of the Chief Financial Officer and management review controls.

Key points

  • Dismissal of CBIZ CPAs effective October 14, 2026; CBIZ CPAs' reports for fiscal years ended April 30, 2026 and 2025 contained no adverse opinion, disclaimer, or qualification
  • Grassi & Co. approved October 14, 2026 to audit fiscal year ending April 30, 2027 and review interim statements starting with the quarter ending October 31, 2026
  • Disclosed material weaknesses relate to insufficient segregation of duties of the Chief Financial Officer and insufficient management review controls
  • CBIZ CPAs letter dated October 16, 2026 filed as Exhibit 16.1

The filing

CompanyPharmaCyte Biotech, Inc. (PMCB)
Form8-K, current report
Filed with the SECOct 16, 2026, 5:00 PM ET
Accession number0001683168-26-007934

Items reported: 4.01 Auditor Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.